Format

Send to

Choose Destination
Breast Cancer Res Treat. 2016 Sep;159(2):203-13. doi: 10.1007/s10549-016-3935-4. Epub 2016 Aug 13.

First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Author information

1
Brust-Zentrum Zürich, Seefeldstr. 214, 8008, Zurich, Switzerland. c.rageth@brust-zentrum.ch.
2
Centre du sein, Département de Gynécologie et d'Obstétrique, Hôpitaux Universitaires de Genève, Bd de la Cluse 30, 1211, Genève 14, Switzerland. c.rageth@brust-zentrum.ch.
3
Institute of Cancer Research and Royal Marsden Hospital, London, UK.
4
Memorial Sloan Kettering Cancer Center, Breast and Imaging Center, 300 E 66th St Suite 723, New York, NY, 10065, USA.
5
Institut für Radiologie und Nuklearmedizin, Luzerner Kantonsspital, 6000, Lucerne, Switzerland.
6
Institute of Radiology, Department of Medical Services, Kantonsspital Baden, im Ergel, 5404, Baden, Switzerland.
7
DKD HELIOS Klinik, Aukammallee 33, 65191, Wiesbaden, Germany.
8
Imagerie du Flon, Vigie 5, 1000, Lausanne 20, Switzerland.
9
Centro di Radiologia e Senologia Luganese, Corso Pestalozzi 3, 6900, Lugano, Switzerland.
10
Marienhospital Osnabrück, Bischofsstraße 1, 49074, Osnabrück, Germany.
11
Brust-Zentrum Zürich, Seefeldstr. 214, 8008, Zurich, Switzerland.
12
Institut für Pathologie am Dietrich-Bonhoeffer-Klinikum, Salvador-Allende-Straße 30, 17036, Neubrandenburg, Germany.
13
Centre du sein, Centre Hospitalier, Universitaire Vaudois, 1011, Lausanne, Switzerland.
14
Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland.

Abstract

The purpose of this study is to obtain a consensus for the therapy of B3 lesions. The first International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) including atypical ductal hyperplasia (ADH), flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL), benign phyllodes tumors (PT), and radial scars (RS) took place in January 2016 in Zurich, Switzerland organized by the International Breast Ultrasound School and the Swiss Minimally Invasive Breast Biopsy group-a subgroup of the Swiss Society of Senology. Consensus recommendations for the management and follow-up surveillance of these B3 lesions were developed and areas of research priorities were identified. The consensus recommendation for FEA, LN, PL, and RS diagnosed on core needle biopsy or vacuum-assisted biopsy (VAB) is to therapeutically excise the lesion seen on imaging by VAB and no longer by open surgery, with follow-up surveillance imaging for 5 years. The consensus recommendation for ADH and PT is, with some exceptions, therapeutic first-line open surgical excision. Minimally invasive management of selected B3 lesions with therapeutic VAB is acceptable as an alternative to first-line surgical excision.

KEYWORDS:

B3 lesions; Breast; Breast surgery; Consensus; Uncertain malignant potential; Vacuum-assisted biopsy

PMID:
27522516
PMCID:
PMC5012144
DOI:
10.1007/s10549-016-3935-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center